{"name":"Omega Therapeutics","slug":"omega-tx","ticker":"OMGA","exchange":"NASDAQ","domain":"omegatx.com","description":"Omega Therapeutics is a biotechnology company focused on epigenomics and gene regulation. The company is developing a pipeline of therapeutics, including its lead program, OTX-200, for the treatment of autoimmune and inflammatory diseases. Omega Therapeutics has a strong presence in the gene regulation space and is working to bring innovative treatments to patients. With a focus on epigenetic modulation, the company aims to address unmet medical needs in various therapeutic areas.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Mahesh Karande","sector":"Epigenomics / Gene Regulation","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":3094000,"revenueGrowth":49.3,"grossMargin":0,"rdSpend":77169000,"netIncome":-97428000,"cash":204366000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"OTX-200 patent cliff ($0.0B at risk)","drug":"OTX-200","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Omega Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Omega Therapeutics Announces Collaboration with Leading Research Institution","summary":"Omega Therapeutics entered into a collaboration with a leading research institution to advance its epigenetic modulation platform.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2025-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-02-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxON1h1QmJJaDNKWWRsM2F3S2I0dUlYaEtrMExsd3Rzb21HSVZGMG9iYk8wMmM5cmpNUVJENm51Q2xER1pQMnFCQWhlZWpMNjVVWjJCaGlWQmZlWUxWQm1QYkZZRHNReXVlbGdUazdFOGpiOUlfTTlqdzlHOV9BSXhPMndrckxRQllmNE0tRmRlVTF3VXpQSTFBX1ozOGlsOVNT?oc=5","date":"2025-02-04","type":"pipeline","source":"BioPharma Dive","summary":"Flagship-backed Omega signals it’s headed toward bankruptcy - BioPharma Dive","headline":"Flagship-backed Omega signals it’s headed toward bankruptcy","sentiment":"neutral"},{"date":"2025-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-01-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-01-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-12-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-11-14","type":"trial","source":"GlobeNewswire","summary":"Omega Therapeutics Announces Successful Completion of Phase - GlobeNewswire","headline":"Omega Therapeutics Announces Successful Completion of Phase","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbGVSU0hhMUVnNXlpSS11UHljUHlLRzhVZHFsN2NrM2hQcHFpVjUzVnVOTEIyMXU5YjlSaGhJZHEwOXhzUFJzQXhNNmpTamotMGxYNy1SeGxncUNXRDFxTjk5UEkzUXpqNGd5SkVXOXp0elhIcjAwYWdSdC15YWRfM3gyMnRuOGxndjZVYklZYnRqRW8zMDl5bDFmdlRCTzZHdmRCcjFGM0JGMklETHk4OFpWaEdXd2VSSHAxN1Nyb0xINlJlTlZpeWw5UWVGN1lqQ01IVVFwazE?oc=5","date":"2024-05-09","type":"pipeline","source":"Reuters","summary":"Novo Nordisk ties up with Metaphore to develop new obesity drugs - Reuters","headline":"Novo Nordisk ties up with Metaphore to develop new obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNODh6WlZDTDZGVHE1czM4S2F5MXMzeWNxZEZYUXl3eGdEQzlEbEw1Ui1VcGhpOTFSWmpIaWNfWWlXYmR0eEZud0Rwek5MZzJkYlBNekJzeGxweURyRFRyb3QzSDNIR1RGbVJGemUwYi1aYTJrdUpvUFZRbWUzMDJHc2RPb18tREFHMHUwcGJZeW9LekdHX0ZZUzVKRFVGWVoyOUVzMWJqM3VRejlsQ0dJOVh6ZENKQk1aWXVz?oc=5","date":"2024-01-08","type":"pipeline","source":"Investor's Business Daily","summary":"It's Been An Abysmal Two Years. But Biotech Is Looking Up. - Investor's Business Daily","headline":"It's Been An Abysmal Two Years. But Biotech Is Looking Up. - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPRVdQM2JFeTdsM1A5SUd0SGtFUzEyYm1QbTJRcXVlaHFDZjUyRGlYWFhmYVJBemRXNXh0MjFhNkRKVmZEYXZaLW9WR2h5MVc3c3pxV2Q0eUJXRm1NeWhQN3lkWENLQy1zZk92VWh1UUlBZ1dSWXhMN2ZIb1hEaDJyZ2hxdXl1VnZFeFR4R25lV29meVVaQ1M4S1cyWHB2eHpvVXJVa0hrZS1jNGFRanpHQjNhZW1zZHlHZ0dVNzlMM2tKVTFLZmhuZE1wT2N3Nl9UTGl2LW1Da3BvQWVjVU5LcQ?oc=5","date":"2024-01-04","type":"pipeline","source":"Reuters","summary":"Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms - Reuters","headline":"Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQbV9vdTh2aXhkM3AtaUEzdk4zZFgwZGlEMFk3X0NZNkk4M0xEWXFaek5MX2RWd1VRSDVOek1mX1pqb3RkZlhkTmFua2ZpcDctbDBVRnlXVFMwUk5abEU2Y240LW1lQlJrQ21jaHlyVDZnOXRoRUtQRGF2dmpxR25JQmV3cDdSVmc1dlZ5SGNVaURsU1lTTE8tdGFWMmRVbmFMYjhBQk1ST3ZEdk9DNDdiY0tiSGdIMU5jekhnb0JNWXoteUIxRnRNZEtUUjNORmFrcDhNQ19wWUlwM0FSUWlwVV9aQVV1VmJLTDFxUjgtNTZ0ZFZXWkhKenlxWUlTemJwYl9xcVpOWWJlZG4wNnhPS0pZTE1ZajA1ZlM4S19MeEJmUGxpR2ZWWDJVSXFKZUZwdE11QVYxQ0phNkZBTFE?oc=5","date":"2024-01-04","type":"deal","source":"GlobeNewswire","summary":"Novo Nordisk enters into research collaborations with Omega - GlobeNewswire","headline":"Novo Nordisk enters into research collaborations with Omega","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQSjd2bDJXNmRKUElKQmF3REVrYnd2bURTbHRzd0F0eGtBUFRmdlZ3dXlBdXhpaXZ5Z09US2JWdU9ZSndNd2N6azlsNTdMbGhFNDN5WFdISmV5Q0hzV3BreXpiWkpPbGN0bzh3MEVWemg5eVgyRmlTQzdVY2JIZVZnWnVKeWdub2RFZmhabjNNSmhPUGNGZVlr?oc=5","date":"2022-12-08","type":"pipeline","source":"citybiz","summary":"KSQ Appoints Mahesh Karande to its Board of Directors - citybiz","headline":"KSQ Appoints Mahesh Karande to its Board of Directors","sentiment":"neutral"}],"patents":[{"drugName":"OTX-200","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Autoimmune and Inflammatory Diseases","Gene Regulation"],"financials":{"source":"sec_edgar+yahoo","revenue":3094000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":3094000,"period":"2023-12-31"},{"value":2073000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":77169000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-97428000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":204366000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}